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Diblock copolymer nanoparticles encapsulating a paclitaxel prodrug, Propac 7, have been used to demonstrate the usefulness of
a nonmetabolizable radioactive marker, cholesteryl hexadecyl ether (CHE), to evaluate nanoparticle formulation variables. Since
CHE did not exchange out of the nanoparticles, the rate of clearance of the CHE could be used as an indicator of nanoparticle
stability in vivo. We simultaneously monitored prodrug circulation and carrier circulation in the plasma and the retention of CHE
relative to the retention of prodrug in the plasma was used to distinguish prodrug release from nanoparticle plasma clearance.
NanoparticleslabelledwithCHEwerealsousedtoevaluateaccumulationofnanoparticlesinthetumour.Thismarkerhasprovided
relevant data which we have applied to optimise our nanoparticle formulations.
1.Introduction
Nanoparticle drug carriers improve the therapeutic beneﬁt
of chemotherapeutic agents by exploiting the enhanced per-
meability and retention (EPR) of solid tumours to improve
localised chemotherapeutic drug accumulation ([1], as re-
viewed in [2]). One such drug carrier is the nanoparticle
which forms through the self-association of amphiphilic di-
block copolymers in aqueous environments. The hydropho-
bic core of these nanoparticles provides a reservoir which
can serve as an in vivo carrier of hydrophobic drugs, and
the hydrophilic shell confers compatibility with intravenous
injection [3, 4]. Drug delivery eﬀectiveness is dependent on
circulation stability of the vehicle, the degree of retention of
drug by the vehicle in the circulation, and on the level of
accumulation of encapsulated drug in the targeted tumour
[5]. Retention of encapsulated drug in the plasma during
the early distribution phase of the carrier is crucial for max-
imising drug delivery to solid tumours since particles must
remain in the circulation for at least 6h to achieve the EPR
eﬀect [2]. Importantly, delivery is also tumour dependent
given that the EPR eﬀect is inﬂuenced by characteristics of
the tumour such as the size and number of discontinuities in
the endothelium, the interstitial tumour ﬂuid pressure, and
the tumour size (as reviewed in [6]).
Understanding the in vivo stability of the nanoparticle
is vital to optimise nanoparticle formulation variables [1,
5]. Chemical characteristics of the stabiliser, size of the
polymer, the size of nanoparticles, the drug/polymer ratio,
and compatibility between the drug the nanoparticle core all
have the potential to impact nanoparticle stability [7, 8]. For
instance, since self-associations between the core-forming
hydrophobic portion of the copolymer contributes to the
stability of the nanoparticle, incorporating drugs into the
core can impact these stabilising forces [9, 10]. Potentially,
too high a drug/polymer ratio could increase the rate of
release of drug from the nanoparticle in the circulation and
thereby reduce amount of encapsulated drug reaching the
tumour. Subtle changes in nanoparticle composition may
then ultimately inﬂuence chemotherapeutic eﬃcacy. There
are many in vitro assays of nanoparticle stability; however
these assays correlate poorly with in vivo nanoparticle cir-
culation longevity and nanoparticle drug retention [7]. To
understand the eﬀect of our formulation variables on drug2 Journal of Drug Delivery
release in vivo and on the accumulation of the nanoparticle
at the tumour site and on the release of entrapped agent at
the tumour we needed to track the nanoparticle carrier and
the entrapped agents simultaneously in vivo.
Oneindicationofparticlestabilitycanbemadebysimply
following the level of the entrapped drug circulating in the
plasma over time. Since agents entrapped in vehicles are
protected against metabolism all drug in the plasma can be
considered to be drug retained in the carrier [11]. However
loss of drug from the circulation does not distinguish
between release of the drug from the carrier and drug cleared
entrapped within the carrier. Historically, diblock copolymer
nanoparticleshavebeenfollowedbydirectchemicallabelling
of the unit copolymer concomitant with demonstration of
continued association of the labelled copolymer unit with
the assembled nanoparticle in plasma samples [12, 13].
Following a single nanoparticle in this manner can be
prohibitively labour intensive and thus tracing the plasma
circulation and biodistribution of the carrier portion of the
nanoparticle has rarely been done. We have elected to use
an entrapped agent to follow our nanoparticles. Arguably an
agent that is employed in such minute quantities as to not
impact the stability of the core, that is very well retained
by intact particles and that does not exchange into plasma
lipids or proteins could prove useful to track nanoparticles
in vivo. Cholesteryl hexadacyl ether (3[ H ]C H E )i sa
nonmetabolizable hydrophobic compound widely used to
radioactivelylabelliposomalnanoparticlesandnotknownto
exchange between membranes [14]. Here we have modiﬁed
this approach by incorporating CHE into diblock copolymer
nanoparticles and we demonstrate that monitoring the CHE
provided credible and valuable information which aided in
formulating diblock copolymer nanoparticles.
In a previous report, we described a series of paclitaxel
prodrugs, Propac 1 to Propac 9, and detailed the in vitro
stability, plasma circulation characteristics, and antitumour
eﬃcacyofnanoparticlesformulationsoftheseprodrugs[15].
Propac 7, is a prodrug in which paclitaxel is conjugated via a
diglycolate linker to a C22 acyl chain. This prodrug is readily
hydrolysed to paclitaxel in plasma. The nanoparticles were
comprised of a stabiliser, 2.5K PEG-3K PS, a costabilising
lipid (POPC), and a prodrug and the nanoparticles formed
through ﬂash coprecipitation. The lipid tail of the costabilis-
ing lipid inserts into the hydrophobic core of the nanopar-
ticle while the polar headgroup localises the lipid to the
interface between the hydrophobic core and the hydrophobic
shell of the nanoparticle. The costabilising lipid is necessary
to prevent hydrolytic cleavage of the prodrug during storage
[15]. In order to optimise our carrier formulation we
employed CHE to monitor nanoparticles prepared with a
variety of diblock copolymers stabilisers and at a number of
diﬀerentcomponentratios.Wethenusedthisinformationto
modify the nanoparticle drug retention characteristics and
to investigate the impact of nanoparticle formulation on
accumulation of the nanoparticles in tissues or in tumours.
The simplicity of this approach has allowed us to generate a
rapid and simple screening method which we used to assess
the behaviour of many polymer formulations without neces-
sitating the generation of speciﬁc covalently linked markers.
2.MaterialsandMethods
2.1. Materials. The following copolymer stabilisers were
obtained from Polymer Source (Dorval, Canada); polyethy-
lene 2.5K glycol-polystyrene 3K (PS), polyethylene gly-
col 2K-poly (DL)-lactide 3.9K (PLA), and polyethy-
lene glycol 5K-polycaprolactone 6K (PCL). The pegy-
lated lipid 2-distearoyl-sn-glycero-3-phosphoethanolamine-
N[amino(polyethylene glycol)-2000] (DSPE-PEG2K) was
purchased from Avanti Polar Lipids (Alabaster Al, USA).
Palmitoyloleoylphosphatidylcholine(POPC)waspurchased
from Northern Lipids, Burnaby, Canada. 3[H] cholesteryl
hexadecylether,45Ci/mmol,(3[H]CHE)wasobtainedfrom
Perkin Elmer Life and Analytical Sciences, Inc. (Waltham
MA, USA). Ultima Gold scintillation ﬂuid was purchased
by PerkinElmer Life and Analytical Sciences (Boston, Mas-
sachusetts). Paclitaxel was purchased from Indena S.P.A.,
Milan, Italy. All solvents used were obtained from VWR
International, Mississauga ON, Canada. Foxn1nu athymic
nude mice (7-8 weeks) were obtained from Harlan (Indi-
anapolis IN, USA). HCT-116 tumour human colorectal car-
cinoma cells. paclitaxel-prodrug, 2 -O-(5 -O-docosanyldi-
glycoloyl)-paclitaxel(Propac7)wassynthesisedaspreviously
described [15].
2.2. Nanoparticle Formation and Characterization. Nano-
particle formation using ﬂash coprecipitation has been
described previously [15, 16]. Brieﬂy, nanoparticles with-
out drugs were prepared by dissolving 40mg of poly-
m e r ,P S ,P L A ,P C L ,o rD S P E - P E G 2 K ,i n2 m Lo fe t h a -
nol:tetrahydrofuran(4:1v/v).Thissolutionwasmixedwith
water using an impinging jet mixer with ﬂow rates set
at 6mL/min (solvent) and 59mL/min (water) using two
Harvard Apparatus PHD 2000 syringe pumps. To prepare
prodrug loaded nanoparticles Propac 7, POPC, and PS
were combined at the indicated component ratio in eth-
anol: tetrahydrofuran (4:1v/v) and mixed with water as
for the drug-free nanoparticles. 3[H] CHE-labelled nano-
particles were prepared by adding CHE to the solvent
mixture prior to nanoparticle formation. For plasma clear-
ance studies, 2.5µCi 3[ H ]C H E / 4 0 m go fp o l y m e rw a s
added(0.0000030CHE/copolymer(w/w)).Nanoparticlesfor
biodistribution studies were prepared with 4-fold higher
amountsofradioactivelabel.Solventwasremovedbydialysis
in Spectrum Laboratories 3500MW cut-oﬀ dialysis tubing
(Spectrum Laboratories, Rancho Dominguez CA, USA)
against water. Nanoparticles were concentrated in 300mM
sucrose by crossﬂow dialysis using a 100kD (0.5mm lumen,
60cm path length) MidGee hoop cartridge (GE Healthcare
Life Sciences, Piscataway NJ, USA). The ﬁnal Propac 7 con-
centration was determined by HPLC. The prodrug encapsu-
lation eﬃciency of this procedure was >90%. Nanoparticle
size characteristics were determined by dynamic light scat-
tering in water using a Malvern Zetasizer Nano-ZS (Malvern
Instruments, Worcestershire, UK). Volume weighted hydro-
dynamic diameters were calculated using the Stokes-Einstein
equation.Journal of Drug Delivery 3
2.3. Quantiﬁcation of Paclitaxel Prodrug. Propac 7 was quan-
tiﬁed on a Waters HPLC using a Phenomenex SynergiFusion
analytical column. Plasma samples or nanoparticle suspen-
sions (50µL) were mixed with 150µL of diluents (metha-
nol:acetonitrile, 2:1v/v) by vigorous vortexing and Propac
7 was recovered in the 10000×g supernatant. The mobile
phase consisted of a linear gradient from methanol/10mM
sodium acetate buﬀer (pH 5.6) (70:30v/v) to 100% meth-
anol at a ﬂow rate of 1mL/min. Column temperature was
s e ta t3 0 ◦C. A 20µL sample was injected onto the column
and peak area was monitored by UV detection at 227nm.
Samples in the autosampler were maintained at 4◦Cp r i o rt o
HPLC analysis.
2.4. Column Chromatography of Nanoparticles. Separation of
nanoparticles from the bulk protein fraction was performed
on a 20cm × 1cm Sepharose 4B (GE Healthcare Life
Sciences, Piscataway NJ, USA) column equilibrated within
HEPES buﬀered saline, pH 7.4 at a ﬂow rate of 0.5mL/min.
Plasma samples (200µL) were loaded onto the column and
150µL fractions were collected and aliquots of each fraction
were analyzed for 3[H] CHE in Ultimagold scintillation ﬂuid
(PerkinElmer,NorwalkCT,USA)orcountedonaBeckman-
Coulter LS 6500 scintillation counter and for protein using
PiercemicroBCAassay(ThermoscientiﬁcRockfordIL,USA)
andreadusingaVictorMultilabelplatereader(PerkinElmer,
Norwalk CT).
2.5. Pharmacokinetic Proﬁle. All animal experiments were
conductedaccordingtoprotocolsapprovedbytheUniversity
of British Columbia’s Animal Care Committee and in
accordance with the current guidelines established by the
CanadianCouncilofAnimalCare.Nanoparticlesweresterile
ﬁltered through 0.22 micron ﬁlters then injected into mice
via the tail vein at a dose of 10µL/g body weight up to a
maximum of 250µL. Whole blood was collected into EDTA
coated microtainer tubes (BD Biosciences Bedford, MA,
USA). Plasma was collected by centrifugation of the tubes
at 2800rpm for 10 minutes and stored −20◦C until analysis.
The quantity of Propac 7 in (50µL) aliquots was analyzed
by HPLC. A second 50µL aliquot of each sample was
measured for nanoparticle carrier by monitoring the 3[H]
CHE by liquid scintillation counting with a LS 6500 Multi-
Purpose Scintillation Counter; Beckman Coulter Canada
Inc. (Mississauga ON, Canada).
We determined the plasma half-life, the time to reach
1/2 of the initial Propac or 1/2 of the initial nanoparticle
concentration, from the plasma concentration versus time
curve. The initial nanoparticle concentration was calculated
usingtheplasmavolume.Wehavepreviouslydeterminedthe
plasma volume of Foxn1nu mice averages 0.043mL per gram
o fb o d yw e i g h tu pt oab o d yw e i g h to fu pt o2 5g .
2.6. Tumour and Tissue Accumulation of Radioactive Na-
noparticles. Athymic nude Foxn1nu Mice were injected s.c.
with 2 × 106 colorectal carcinoma HCT-116 cells. Tumour
volumes were determined using digital callipers using the
equation(length ×width2)/2. 3[H]CHE-labellednanoparti-
cles, Propac 7/POPC/PS 1:1:2 (w/w/w) were injected when
tumours reached an average size of 200mm3.T u m o u r s ,
tissue, and blood were collected at 1, 4, 8, 16, 24, and 48
hourspostinjection.Tissuesandtumourswerewashedinice
cold saline and immediately frozen. Blood was centrifuged
and the plasma fraction was recovered and stored frozen
at −20◦C until analysis. Tissue samples were digested in
solvable (GE Health) at 60◦C overnight then decolourised
with H202. 3[H] CHE levels were determined by liquid scin-
tillation counting.
2.7. Statistical Analysis. Data values are reported as mean
± standard deviation (SD). A standard one-way analysis of
variance (ANOVA) was used to determine statistically signif-
icant diﬀerences from the mean. P<0.05 was considered
signiﬁcant for all statistical tests.
3. Results and Discussion
3.1. Nanoparticle Formation and Characterisation. We have
previously described paclitaxel prodrug nanoparticles gen-
erated through ﬂash coprecipitation [15]. When the initial
total concentration of the prodrug, colipid, and diblock
copolymer stabiliser in the solvent was less than 40mg/mL,
this procedure produced small, homogeneous nanoparticles
with a prodrug trapping eﬃciency of >90%. All nanoparticle
solutions were clear with no precipitate and no visible
haze. Nanoparticle size characteristics were determined by
dynamic light scattering in water. Nanoparticles prepared
without prodrug were 10–20nm in diameter by DLS. Propac
7/POPC/PS 1:1:2 (w/w/w) nanoparticles had a mean diam-
eter of 20–30nm and unimodal size distributions suggesting
a single population of nanoparticles. The prodrug stability
was monitored by HPLC and the particle physical stability
over time was monitored by DLS. When maintained at 4◦C
for 11 weeks, less than 5% of Propac 7 was hydrolysed and
nanoparticle size increased by less than 15% [15].
3.2. CHE as a Nanoparticle Marker In Vivo. We used column
chromatographytodemonstratethestrongretentionofCHE
in nanoparticles during both in vitro and in vivo exposures
to plasma and we provide examples of each in Figure 1.
We prepared a 20cm sepharose 4B column and estab-
lished that nanoparticles eluted before the bulk protein frac-
tion on this column. Nanoparticles incubated with mouse
plasma at 37◦C for one hour in vitro gave the same 3[H]
elution proﬁle as control nanoparticles (in water) (data not
shown). Figure 1(a) shows data from an in vivo experiment
in which 3[H] CHE–labelled Propac 7/POPC/PS 1:1:2
(w/w/w) nanoparticles were injected i.v. into mice and plas-
ma was recovered 24 hours later. Plasma was immediately
chromatographed on the column and aliquots of the col-
lected fractions were assayed for protein or 3[H]. The 3[H]
chromatographic elution proﬁle of nanoparticles recovered
from the plasma were unchanged from that of the control
nanoparticles. These data suggest that 3[H] CHE remained
associated with our nanoparticles in plasma and did not4 Journal of Drug Delivery
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Figure 1: Column chromatography of nanoparticles. (a) Plasma from mice injected i.v. with 3[H] CHE-labelled Propac 7/POPC/PS 1:1:2
nanoparticles fractionated on a sepharose 4B column in HEPES buﬀered saline, pH 7.4. Column aliquots of were assayed for protein and
3[H]. The concentration of protein and 3[H] CHE for each fraction are plotted. (b) Plasma from mice injected i.v. with 3[H] CHE-labelled
DSPE-2K nanoparticles were incubated either in water at room temperature or in mouse plasma at room temperature for one hour then
fractionated on a sepharose 4B column. Column aliquots of were assayed for protein and 3[H]. The concentration of protein and 3[H] CHE
for each fraction are plotted.
exchange out of the nanoparticles and associate with plasma
lipoproteins in vivo or in vitro.
We strengthened the contention that CHE does not
transfer to plasma proteins or lipids by incubating relatively
unstable DSPE-PEG2K nanoparticles with plasma in vitro.
DSPE-PEG2K nanoparticles have transition temperature
of 15◦C, and thus the lipid chains assume a disorder
state well below physiological temperatures [17]. In the
presenceofbovineserumalbuminproteinorhumanplasma,
DSPE-PEG2K nanoparticles disaggregation to monomers
begins within minutes [18]. DSPE-PEG2K nanoparticles
were chromatographed on a sepharose 4B column and the
elution proﬁle of the radioactivity is shown in Figure 1(b).
The 3[H] associated with DSPE-PEG2K nanoparticles elutes
as a single sharp peak. We then incubated DSPE-PEG2K
nanoparticles in mouse plasma for one hour at room
temperature and chromatographed this sample on the same
sepharose 4B column. Aliquots of these collected fractions
were assayed for protein or 3[H] and the elution proﬁle is
also shown in Figure 1(b). The bulk of the 3[H] coelutes
with the nanoparticles; however a trailing shoulder peak
appears in the serum treated chromatograph is indicative
of some degree of nanoparticle disruption. Importantly
radioactivity is not found associated with the bulk protein
fraction implying that the CHE did not redistribute to the
lipoproteins.
3.3. 3H-CHE Monitoring Plasma Clearance of Various Sta-
bilisers. We have found 3[H] CHE generally applicable to
correlating nanoparticle formulation variables and in vivo
plasma circulation including varying the stabilisers. We
prepared 3[H] CHE-labelled nanoparticles with various
stabilisers, in this instance, without colipid or prodrug
(Table 1) and the plasma circulation characteristics of these
nanoparticles are shown in Figure 2. The data from PS
nanoparticles is shown in Figure 2(a). Approximately 50% of
the 3[H] label remained 24 hours after injection, suggesting
very stable, long circulating nanoparticles are formed with
this copolymer. The more rapid clearance of 3[H] associated
with PLA and PCL (Figures 2(b) and 2(c), resp.) suggests
that these nanoparticles have lower in vivo stability than
the PS nanoparticles. Finally, we included DSPE-PEG2K
nanoparticles, which have been demonstrated to be unstable
in plasma in vitro [17, 18]. We contend that the in vivo
stability will also be poor for these nanoparticles and should
clear very rapidly from the circulation. We also predicted
that if CHE from DSPE-PEG2K nanoparticles exchanged
into plasma, we would observe a contradictorily prolonged
3[H] circulation. The rapid in vivo clearance of 3[H]
associated with the DSPE-PEG2K nanoparticles Figure 2(d)
suggested that 3[H] CHE lost from these nanoparticles did
not exchange to plasma lipids or lipoproteins.
3.4. Simultaneous Monitoring of Circulating Nanoparticle
Formulation and Prodrug Release. To develop an assay to
monitor the eﬀect of formulation parameters on prodrug
release in vivo, we needed to monitor nanoparticle and pro-
drug plasma circulation simultaneously and independently.
We prepared 3[H] CHE-labelled PS nanoparticles with
prodrug and colipid; Propac 7/POPC/PS 1:1:2 (w/w/w).
These nanoparticles were injected i.v. into mice and plasma
was assayed for both 3[H] and Propac 7. The circulationJournal of Drug Delivery 5
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Figure 2: Plasma clearance of alternate polymer stabilisers. (a) 3[H] CHE-labelled PS. (b) 3[H] CHE-labelled PLA. (c) 3[H] CHE-labelled
PCL. (d) 3[H] CHE-labelled DSPE-PEG2K. Each data point represents the mean (± standard deviation) of three mice.
proﬁles of the 3[H] and the prodrug are shown in Figure 3.
To aid with the interpretation of data, we have reproduced
the data for the nanoparticles without colipid or prodrug
(Figure 2(a)). These results provided information about the
nanoparticle stability and about prodrug retention in vivo.
First, by comparing the circulation of 3[H] associated with
nanoparticles with and without prodrug, we were able to
gauge the eﬀect of encapsulating agents into the core of
the nanoparticle. Long 3[H] circulation times were observed
when 3[H] CHE was incorporated into nanoparticles with-
out prodrug (t1/2 > 24 hours). A signiﬁcant shortening of
3[H] circulation time was observed when colipid and Propac
7 were introduced into the nanoparticles (t1/2 14 hours).
We attributed the enhanced clearance of 3[H] associated
with prodrug loaded nanoparticles to a less stable nanopar-
ticle formed when the prodrug was incorporated into the
nanoparticle. Secondly, by simultaneously monitoring 3[H]
and Propac 7 in prodrug loaded nanoparticles we were
able to demonstrated prodrug clearance was faster than
particle clearance. This suggested that the prodrug clearance
occurred through both release of the prodrug from the na-
Table 1: Stabilisers 3[H] CHE-labelled nanoparticles.
Polymers Size nm (diameter)
PEG2.5-PS3K 16.3
PLA3.9K-PEG2K 9.3
PCL6K-PEG5K 18.9
DSPE2K-PEG 10
noparticle and nanoparticle clearance. It is noteworthy that
we have not always observed prodrug in plasma clearing
faster than 3[H]. In a previous report we observed prodrug
cleared at a rate equal to that of the 3[H] [15]. This occurred
when nanoparticles were loaded with a nonmetabolisable
paclitaxel drug conjugate, suggesting that in this instance all
prodrug was being cleared still associated with the nanopar-
ticle.
In a further set of experiments we demonstrated that
we could monitor the eﬀect of formulation composition
on particle clearance. We prepared a series of 3[H] CHE-
labelled Propac 7/POPC/PS nanoparticles with component6 Journal of Drug Delivery
Table 2: Component weight ratios of formulations of Propac 7. Diameter of particles is the volume weighted average diameter and Zave of
the diameter.
Formulation w/w/w Diameter nm Zave nm
Propac 7/POPC/PS 1:1:4 20.9 23.8
Propac 7/POPC/PS 1:1:2 26.6 31.2
Propac 7/POPC/PS 1:1:1 34.9 40.5
Propac 7/POPC/PS 2:2:1 43.6 54.8
2.5K PEG-3K PS (3H-CHE)
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Figure 3:Plasma 3[H]clearanceof 3[H]CHE-labelledPSnanopar-
ticles or plasma clearance of CHE-labelled Propac 7/POPC/PS
1:1:2 nanoparticles. The 3[H] CHE plasma proﬁle is shown for
the PEG-3K PS nanoparticles and both the 3[H] CHE-labelled and
Propac 7 proﬁles are shown for the Propac 7/POPCPS nanoparti-
cles. Each data point represents the mean (± standard deviation)
of three mice. Clearance of Propac 7/POPC/2.5K PEG-3K PS is
signiﬁcantly faster than drug-free nanoparticles (P<0.05 at each
time points).
weightratiosof1:1:4,1:1:2,1:1:1,and2:2:1(w/w/w)
(Table 2).Themeandiametersofthenanoparticlesincreased
as the prodrug/polymer ratio increased. The data for 3[H]
plasma clearance following injection of these nanoparticles
is shown in Figure 4. The particles with the lowest amount
of prodrug relative to polymer, Propac 7/POPC/PS 1:1:4
(w/w/w) had the smallest particle sizes and long 3[H] CHE-
circulationlifetimes.Increasingtheprodrug/polymerratioin
Propac 7/POPC/PS 1:1:2 (w/w/w) generated nanoparticles
with 30% larger diameters, however the plasma clearance of
the 3[H] was unchanged relative to the Propac 7/POPC/PS
1:1:4 (w/w/w) nanoparticles. This suggests that in vivo
stability of these particles was not impacted by the increase
in prodrug. Nanoparticles with Propac 7/POPC/PS 1:1:1
and 2:2:1 (w/w/w) formed larger nanoparticles and had
faster 3[H] CHE-plasma clearances. These results suggested
that the nanoparticles formed with this diblock copolymer
stabiliser have a tolerance limit for the amount of prodrug
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Figure 4: Plasma 3[H] proﬁle of 3[H] CHE-labelled Propac 7/
POPC/PS prepared at diﬀerent polymer ratios. 3[H] CHE-labelled
nanoparticles were prepared with 4 diﬀerent ratios of Propac 7 and
PS. Data for 3[H] levels is plotted. Each data point represents the
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which can be incorporated into the hydrophobic core. This
information was used to determine the maximum nanopar-
ticle drug content obtainable with minimal impact of nano-
particle stability.
In addition to varying component ratios and stabilisers,
we have used 3[H] CHE labelling to evaluate the role of
alternate costabilisers (vitamin E-succinate or phosphatidyl-
glycerol) [15], and for nanoparticles loaded with diﬀerent
paclitaxel prodrugs or with hydrophobic prodrugs of other
chemotherapeutic agents (gemcitabine and doxorubicin)
(not shown). The loading capacity of nanoparticles is likely
unique for each diblock copolymer and diﬀerent for every
drug.Theabilitytotracethenanoparticleinvivoisavaluable
toolforchoosingstabilisersanddeterminingoptimalloading
ratios. Importantly, labelling nanoparticles by physically
incorporating CHE is technically quite simple.
3.5. Tissue and Tumour Accumulation of Nanoparticles. To
technique evaluate the utility of this nanoparticle labelling
technique we monitored plasma clearance and tumourJournal of Drug Delivery 7
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Figure 5: Plasma clearance and tissue accumulation of 3[H] CHE-labelled Propac 7/POPC/PS nanoparticles. Plasma 3[H] proﬁle and 3[H]
tissue accumulation from HCT116 tumor-bearing mice injected with 3[H] CHE-labelled Propac 7/POPC/PS 1:1:2 (6mg/kg Propac 7).
Only 3[H] was measured. Data points are the average of two mice. (a) plasma, (b) lung, (c) kidney, (d) spleen, (e) tumor, and (f) liver.8 Journal of Drug Delivery
accumulation of 3[H] CHE-labelled nanoparticles. The goal
was to try to understand the eﬀect of formulation variables
and dosing schedule on eﬃcacy. To demonstrate that we
could monitor nanoparticle accumulation in tissues and
tumours, 3[H] CHE-labelled Propac 7/POPC/PS nanopar-
ticles 1:1:2 (w/w/w) were injected into HCT-116 tumour-
bearing mice. The plasma and tissues were harvested and
the 3[H] levels were measured at various times. The results
in Figure 5 shows plasma clearance of 3[H] associated with
prodrug loaded nanoparticles (Figure 5(a)) and accumula-
tion of 3[H] in the organs and the tumours of the same mice
over a 48-hour period (Figures 5(b)–5(f)). Notably, 3[H]
accumulated in HCT-116 tumours for more than 48 hours
underscoring the need for stable nanoparticles to maximise
chemotherapeutic eﬃcacy.
We have employed 3[H] CHE-labelled nanoparticles in
order to compare accumulations in large and small tumours
of same cell origin and to assess nanoparticle accumulation
in diﬀerent types of tumour (not shown). The reliance of
nanoparticle tumour accumulation on the EPR eﬀect makes
tumour accumulation subject to variables such as the degree
of tumour vascularization. The accumulation of CHE-
labellednanoparticleswasusefultooptimisedosingschedule
and to understand the impact of nanoparticle composition
on tumour eﬃcacy.
4. Conclusion
The in vivo stability of controlled release formulations
critically impacts biodistribution and the pharmacokinetics
of the encapsulated agent. It is imperative to characterise
the eﬀect of formulation variables on carrier stability and
drug retention. Unfortunately in vitro assays of nanoparticle
stability do not predict the stability of nanoparticles in vivo
and labelling of diblock copolymers can be quite labour
intensive. We have used entrapped radioactive agents to label
our nanoparticles for in vivo assessment of nanoparticle
stability. We have found that this label provided relevant
data which accelerated screening of many variables and
which aided in nanoparticle component selection and
optimising component ratios. Furthermore, we further test
selected formulations in eﬃcacy experiments to substanti-
ate our formulation choices made using plasma clearance
data.
As a caution, one must conﬁrm that a noncovalently
incorporated nanoparticle label remains associated with the
nanoparticle in plasma. We veriﬁed this by running size
exclusion chromatographic columns which separated our
nanoparticles from the bulk protein of the plasma and in
every instance, all the 3[H] co-eluted from the column
with nanoparticles. We have never observed transfer of
3[H] to the plasma fraction. One other potential ﬂaw is
an underestimation of nanoparticle stability if the 3[H]
CHE is rapidly released and clearance of the nanoparticles
themselves remain intact. This is a limitation that cannot
be solved without directly labelling the copolymer. The
most meaningful data will ultimately be the antitumour
eﬃcacy.
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POPC: Palmitoyl oleoyl phosphatidylcholine
PS: Polystyrene.
Acknowledgment
The authors wish to thank Joyce Kan and Laura Williams for
their excellent technical assistance.
References
[1] Y. Matsumura and H. Maeda, “A new concept for macro-
molecular therapeutics in cancer chemotherapy: mechanism
of tumoritropic accumulation of proteins and the antitumor
agent smancs,” Cancer Research, vol. 46, no. 12 I, pp. 6387–
6392, 1986.
[2] H. Maeda, “The enhanced permeability and retention (EPR)
eﬀect in tumor vasculature: the key role of tumor-selective
macromolecular drug targeting,” Advances in Enzyme Regula-
tion, vol. 41, pp. 189–207, 2001.
[ 3 ]Y .T e n g ,M .E .M o r r i s o n ,P .M u n k ,S .E .W e b b e r ,a n dK .
Proch´ azka, “Release kinetics studies of aromatic molecules
into water from block polymer micelles,” Macromolecules,
vol. 31, no. 11, pp. 3578–3587, 1998.
[4] G. S. Kwon and K. Kataoka, “Block copolymer micelles
as long-circulating drug vehicles,” Advanced Drug Delivery
Reviews, vol. 16, no. 2-3, pp. 295–309, 1995.
[5] L. D. Mayer, R. Nayar, R. L. Thies, N. L. Boman, P. R.
Cullis, and M. B. Bally, “Identiﬁcation of vesicle properties
that enhance the antitumour activity of liposomal vincristine
against murine L1210 leukemia,” Cancer Chemotherapy and
Pharmacology, vol. 33, no. 1, pp. 17–24, 1993.
[6] D. C. Drummond, O. Meyer, K. Hong, D. B. Kirpotin, and
D. Papahadjopoulos, “Optimizing liposomes for delivery of
chemotherapeutic agents to solid tumors,” Pharmacological
Reviews, vol. 51, no. 4, pp. 691–743, 1999.
[7] H. M. Burt, X. Zhang, P. Toleikis, L. Embree, and W. L.
Hunter, “Development of copolymers of poly(D,L-lactide)
and methoxypolyethylene glycol as micellar carriers of pacli-
taxel,” Colloids and Surfaces B, vol. 16, no. 1–4, pp. 161–171,
1999.
[8] N. Nishiyama and K. Kataoka, “Current state, achievements,
and future prospects of polymeric micelles as nanocarriers
for drug and gene delivery,” Pharmacology and Therapeutics,
vol. 112, no. 3, pp. 30–48, 2006.
[9] M. Chorny, I. Fishbein, H. D. Danenberg, and G. Golomb,
“Lipophilicdrugloadednanospherespreparedbynanoprecip-
itation: eﬀect of formulation variables on size, drug recovery
and release kinetics,” Journal of Controlled Release, vol. 83,
no. 3, pp. 389–400, 2002.
[10] K. M. Huh, S. C. Lee, Y. W. Cho, J. Lee, J. H. Jeong, and
K. Park, “Hydrotropic polymer micelle system for delivery
of paclitaxel,” Journal of Controlled Release, vol. 101, no. 1–3,
pp. 59–68, 2005.
[11] L. D. Mayer, D. Masin, R. Nayar, N. L. Boman, and M. B. Bally,
“PharmacologyofliposomalvincristineinmicebearingL1210Journal of Drug Delivery 9
ascitic and B16/BL6 solid tumours,” British Journal of Cancer,
vol. 71, no. 3, pp. 482–488, 1995.
[12] J. Liu, F. Zeng, and C. Allen, “In vivo fate of unimers and
micelles of a poly(ethylene glycol)-block-poly(caprolactone)
copolymer in mice following intravenous administration,”
European Journal of Pharmaceutics and Biopharmaceutics,
vol. 65, no. 3, pp. 309–319, 2007.
[13] M. Sasatsu, H. Onishi, and Y. Machida, “Preparation and
biodisposition of methoxypolyethylene glycol amine-poly(dl-
lactic acid) copolymer nanoparticles loaded with pyrene-
ended poly(dl-lactic acid),” International Journal of Pharma-
ceutics, vol. 358, no. 1-2, pp. 271–277, 2008.
[14] J. T. P. Derksen, H. W. M. Morselt, and G. L. Scherphof,
“Processing of diﬀerent liposome markers after in vitro
uptake of immunoglobulin-coated liposomes by rat liver
macrophages,” Biochimica et Biophysica Acta, vol. 931, no. 1,
pp. 33–40, 1987.
[15] S. M. Ansell, S. A. Johnstone, P. G. Tardi et al., “Modulating
the therapeutic activity of nanoparticle delivered paclitaxel
by manipulating the hydrophobicity of prodrug conjugates,”
Journal of Medicinal Chemistry, vol. 51, no. 11, pp. 3288–3296,
2008.
[16] B. K. Johnson and R. K. Prud’homme, “Mechanism for rapid
self-assembly of block copolymer nanoparticles,” Physical
Review Letters, vol. 91, no. 11, pp. 1183021–1183024, 2003.
[17] M. Kastantin, B. Ananthanarayanan, P. Karmali, E. Ruoslahti,
a n dM .T i r r e l l ,“ E ﬀect of the lipid chain melting transition on
the stability of DSPE-PEG (2000) micelles,” Langmuir, vol. 25,
no. 13, pp. 7279–7286, 2009.
[18] M. Kastantin, D. Missirlis, M. Black, B. Ananthanarayanan, D.
Peters, and M. Tirrell, “Thermodynamic and kinetic stability
of DSPE-PEG(2000) micelles in the presence of bovine serum
albumin,” Journal of Physical Chemistry B, vol. 114, no. 39,
pp. 12632–12640, 2010.